Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...

Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer ...

Life-saving antibiotics that could treat severe infections in babies and children aren't accessible due to a lack of data ...

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...

In a new draft guidance issued on January 14, 2026, the FDA discussed the use of a modern statistical methodology in clinical trials designed to ...

Licensed scientific and clinical intelligence integrated into the 3RnD platform to support AI-Driven Discovery and ...

• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic ...

U.S. clinical trials for ALS do not include enough non-white patients and women to reflect the disease's real-world prevalence, per a study.

New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures The research assesses how protocol design ...

This article is part of our series on clinical data considerations. Read How to Prepare for Disclosure. For publicly traded biotech companies, disclosing clinical trial data can be an exciting ...